Artwork

Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

New class of small molecule therapeutics introduced

26:35
 
Share
 

Manage episode 385552351 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Chapters

1. New class of small molecule therapeutics introduced (00:00:00)

2. About Gate Bioscience
 (00:00:45)

3. What are disease-causing extracellular proteins? (00:01:06)

4. How have diseases caused by extracellular proteins been treated in the past?
 (00:02:09)

5. Have there been diseases that haven’t been addressed?
 (00:04:44)

6. Tackling the different issues created by extracellular proteins
 (00:05:47)

7. What are molecular gates?
 (00:07:05)

8. How to distinguish between good and bad extracellular proteins
 (00:09:41)

9. How did the idea become a company?
 (00:12:56)

10. Which diseases will you focus on?
 (00:16:24)

11. How do you address costs? (00:17:24)

12. How will this be given to patients? (00:18:47)

13. Disease cure or disease management? (00:19:11)

14. How was Gate created?
 (00:20:01)

15. The rise of small molecules
 (00:21:35)

16. What are the next steps for Gate Bioscience?
 (00:24:18)

104 episodes

Artwork
iconShare
 
Manage episode 385552351 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Chapters

1. New class of small molecule therapeutics introduced (00:00:00)

2. About Gate Bioscience
 (00:00:45)

3. What are disease-causing extracellular proteins? (00:01:06)

4. How have diseases caused by extracellular proteins been treated in the past?
 (00:02:09)

5. Have there been diseases that haven’t been addressed?
 (00:04:44)

6. Tackling the different issues created by extracellular proteins
 (00:05:47)

7. What are molecular gates?
 (00:07:05)

8. How to distinguish between good and bad extracellular proteins
 (00:09:41)

9. How did the idea become a company?
 (00:12:56)

10. Which diseases will you focus on?
 (00:16:24)

11. How do you address costs? (00:17:24)

12. How will this be given to patients? (00:18:47)

13. Disease cure or disease management? (00:19:11)

14. How was Gate created?
 (00:20:01)

15. The rise of small molecules
 (00:21:35)

16. What are the next steps for Gate Bioscience?
 (00:24:18)

104 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide